ARIAD Announces Appointment of Jennifer L. Herron as Chief Commercial Officer
May 24 2016 - 9:25AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the
appointment of Jennifer L. Herron as executive vice president,
chief commercial officer, effective May 31, 2016. She will report
to ARIAD’s president and chief executive officer, Paris
Panayiotopoulos. Ms. Herron will succeed Martin J. Duvall, who has
made significant contributions to ARIAD since first joining the
company in 2011. Mr. Duvall will work closely with Ms. Herron to
ensure a seamless transition.
”I am delighted that Jennifer will be joining ARIAD as our Chief
Commercial Officer,” stated Paris Panayiotopoulos, president and
chief executive officer of ARIAD. “Jennifer is a proven leader with
over 23 years of pharmaceutical experience across multiple
therapeutic areas, specifically oncology, immunoscience and
cardio-vascular/metabolics, which I am confident will serve her
well in maximizing the commercial opportunity for Iclusig® and, if
approved, brigatinib.”
Ms. Herron comes to ARIAD after a ten-year career at
Bristol-Myers Squibb Company (BMS), where she recently accepted the
position of Lead, Commercial Transformation and Operating Model.
Previously, Ms. Herron served in various roles of increasing
responsibility at BMS, including as Vice President, US Immunology
from 2014-2016, where she transformed the U.S. immunoscience
business unit, returning the business to significant volume and
share growth; and as General Manager for BMS in Puerto Rico and the
Caribbean from 2012-2014, where she was responsible for driving
topline performance for the entire BMS portfolio. Ms. Herron also
served as Executive Director, US Commercial Operations, for BMS
from 2010-2012, following several commercial leadership roles in
oncology from 2006 through 2009. Prior to joining BMS, Ms. Herron
served in critical marketing roles for in-line and launch assets in
oncology for both Novartis and GSK/SmithKline Beecham. Ms. Herron
started her pharmaceutical career as a clinical research associate
at Boehringer Mannheim Pharmaceuticals.
“I am excited about this incredible opportunity at ARIAD,”
stated said Ms. Herron. “I look forward to working with the team to
maximize the commercial performance of Iclusig, prepare for the
potential U.S. launch of brigatinib, and collaborate with R&D
colleagues to further advance the pipeline.”
Mr. Panayiotopoulos added, “On behalf of the company’s Board of
Directors, management team and employees, I want to thank Marty for
his tremendous contributions to ARIAD, especially his leadership in
launching and building out the commercial team for Iclusig and
leading our preparations for the potential launch of
brigatinib.”
Ms. Herron earned a Bachelor of Arts in Biology and Economics
from Lehigh University and her MBA from Georgetown University.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an orphan oncology
company focused on transforming the lives of cancer patients with
breakthrough medicines. ARIAD is working on new medicines to
advance the treatment of various forms of chronic and acute
leukemia, lung cancer and other orphan cancers. ARIAD utilizes
computational and structural approaches to design small-molecule
drugs that overcome resistance to existing cancer medicines. For
additional information, visit http://www.ariad.com or follow
ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements, each of
which are qualified in their entirety by this cautionary statement.
Any statements contained herein which do not describe historical
facts, including, but not limited to the statements made by Mr.
Panayiotopoulos and Ms. Herron, are forward-looking statements that
are based on management’s expectations and are subject to certain
factors, risks and uncertainties that may cause actual results,
outcome of events, timing and performance to differ materially from
those expressed or implied by such statements. These factors, risks
and uncertainties include, but are not limited to, our ongoing
strategic review, our ability to successfully commercialize and
generate profits from sales of Iclusig and our product candidates,
if approved; competition from alternative therapies; our ability to
meet anticipated clinical trial commencement, enrollment and
completion dates and regulatory filing dates for our products and
product candidates and to move new development candidates into the
clinic; our ability to execute on our key corporate initiatives;
regulatory developments and safety issues, including difficulties
or delays in obtaining regulatory and pricing and reimbursement
approvals to market our products; our reliance on the performance
of third-party manufacturers and specialty pharmacies for the
supply and distribution of our products and product candidates; the
occurrence of adverse safety events with our products and product
candidates; the costs associated with our research, development,
manufacturing, commercialization and other activities; the conduct,
timing and results of preclinical and clinical studies of our
products and product candidates, including that preclinical data
and early-stage clinical data may not be replicated in later-stage
clinical studies; the adequacy of our capital resources and the
availability of additional funding; the ability to satisfy our
contractual obligations, including under our leases, convertible
debt and royalty financing agreements; patent protection and
third-party intellectual property claims; litigation; our
operations in foreign countries; risks related to key employees,
markets, economic conditions, health care reform, prices and
reimbursement rates; and other risk factors detailed in our public
filings with the U.S. Securities and Exchange Commission, including
our most recent Annual Report on Form 10-K and subsequent Quarterly
Reports on Form 10-Q. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release and we undertake no obligation to update or revise any of
these statements to reflect events or circumstances occurring after
this press release. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release.
Iclusig® is a registered trademark of ARIAD Pharmaceuticals,
Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160524005861/en/
ARIAD Pharmaceuticals, Inc.For InvestorsMaria Cantor,
617-621-2208Maria.cantor@ariad.comorFor MediaLiza Heapes,
617-621-2315Liza.heapes@ariad.com
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Oct 2023 to Oct 2024